Thermo Fisher Scientific Inc. (NYSE:TMO) VP Sells $2,221,584.48 in Stock

Thermo Fisher Scientific Inc. (NYSE:TMO) VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares of the company’s stock, valued at $8,397,760.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Thermo Fisher Scientific Stock Down 0.3 %

Shares of NYSE TMO opened at $613.34 on Thursday. The company has a quick ratio of 1.37, a current ratio of 1.72 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $620.63. The firm’s fifty day moving average is $564.16 and its 200 day moving average is $567.20. The company has a market cap of $234.12 billion, a price-to-earnings ratio of 39.34, a PEG ratio of 2.81 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company had revenue of $10.54 billion for the quarter, compared to the consensus estimate of $10.50 billion. During the same period in the previous year, the firm earned $5.15 earnings per share. The firm’s revenue for the quarter was down 1.4% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Friday, September 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. Royal Bank of Canada raised their price objective on shares of Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. HSBC lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Finally, Stifel Nicolaus lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $618.94.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Signature Resources Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 318.2% during the 2nd quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after buying an additional 35 shares in the last quarter. LifeSteps Financial Inc. bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $31,000. New Millennium Group LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $29,000. Northwest Financial Advisors bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at $29,000. Finally, Stephens Consulting LLC boosted its stake in Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after purchasing an additional 29 shares in the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.